View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
October 28, 2021

Hologic Covid-19/Flu test available in Europe and North America

The Aptima SARS-CoV-2/Flu assay simultaneously detects and differentiates between SARS-CoV-2, influenza A and influenza B.

Hologic has announced the commercial availability of its Aptima SARS-CoV-2/Flu test in North America and Europe.

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

The new multiplex Covid-19/Flu test is designed to simultaneously detect and differentiate between three respiratory viruses, namely SARS-CoV-2, influenza A and influenza B.

These three viruses cause similar symptoms, which can include headache, fatigue, cough and fever.

The Aptima SARS-CoV-2/Flu assay can detect and differentiate the viruses by using the company’s real-time transcription-mediated amplification (TMA) technology.

It uses nasopharyngeal and nasal swab samples, which can be collected from individuals with symptoms of respiratory infections or who meet Covid-19 clinical and epidemiological criteria.

The assay has obtained Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) and is authorised under Health Canada’s Interim Order. It is also CE-marked for diagnostic use in Europe.

It runs on Hologic’s Panther molecular diagnostics system, which is completely automated, delivers first results in about three hours and has the capability to process more than 1,000 tests in 24 hours.

Hologic diagnostic solutions division president Kevin Thornal said: “Our new assay will provide greater flexibility and testing options for labs and healthcare providers as we head into what is typically flu season in the United States.

“Because our Panther instruments are so widely placed in clinical labs across the country, the launch of this test will help deliver results where and when they are needed.”

The company stated that multiple devices can be used for collection, including its Direct Load Collection Kits, which are designed to improve efficiency in laboratories and reduce viral transmission risk.

The new multiplex test development was partly funded with federal funds obtained from the Biomedical Advanced Research and Development Authority; the US Department of Health and Human Services; and the Office of the Assistant Secretary for Preparedness and Response.

Earlier this month, Hologic introduced Novodiag, its molecular diagnostic system for on-demand molecular testing in Europe.

Related Companies

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network